Important Deadline Approaching for Class Action Against Capricor Therapeutics Shareholders
Urgent Notice for Capricor Therapeutics Shareholders
The Gross Law Firm has announced a critical reminder for shareholders of Capricor Therapeutics, Inc. (NASDAQ: CAPR) regarding an impending deadline to join a class action lawsuit. The deadline is set for September 15, 2025, and it is vital for all eligible shareholders who purchased shares between October 9, 2024, and July 10, 2025, to act promptly.
Background of the Case
The class action has been initiated due to allegations against Capricor Therapeutics that the company misrepresented key information regarding its lead drug candidate, deramiocel, which is designed for treating cardiomyopathy associated with Duchenne muscular dystrophy (DMD). It has been reported that the company’s executives provided overly optimistic statements about their ability to secure a Biologics License Application (BLA) from the U.S. Food and Drug Administration (FDA).
As disclosed in the lawsuit, these statements were made despite the company allegedly withholding material information which would have presented a more accurate picture of its safety and efficacy data from the Phase 2 HOPE-2 trial. Following a communication from the FDA on July 11, 2025, which indicated that the application did not meet the required standards and additional clinical evidence was necessary, Capricor's stock plummeted from $11.40 to $7.64 per share in a single day—a drop that has spurred concern among investors.
What This Means for Shareholders
Shareholders who believe they have suffered losses due to these events are encouraged to contact the Gross Law Firm to discuss the possibility of being appointed as lead plaintiffs in the class action. However, it is important to note that appointment as lead plaintiff is not a prerequisite for participating in any potential recovery from the lawsuit. By joining this class action, investors will not incur any costs or obligations.
In addition, once registered, shareholders will benefit from ongoing updates about the lawsuit process through a portfolio monitoring service, ensuring they stay informed about the developments and implications of the case.
Next Steps
To register, affected shareholders should not delay and are advised to provide their information by visiting the Gross Law Firm's submission page. The deadline of September 15, 2025, is fast approaching, and timely action is crucial to securing rights to recovery in this legal matter.
About the Gross Law Firm
The Gross Law Firm has built a strong reputation as a class action law firm focused on protecting the rights of investors impacted by corporate misconduct and malpractice. Their mission is to ensure accountability among public companies while aiding investors who've faced losses due to fraud or illegal practices. This case against Capricor Therapeutics is part of their broader commitment to uphold integrity in the business environment.
For further inquiries or to register for participation in this class action, interested parties can contact the Gross Law Firm at:
- - Address: 15 West 38th Street, 12th floor, New York, NY 10018
- - Email: [email protected]
- - Phone: (646) 453-8903
As this situation continues to develop, shareholders should remain vigilant and proactive in safeguarding their interests.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.